Sleep medicine has changed more in the last ten years than in the previous fifty. CPAP machines went from clunky, noisy boxes to whisper-quiet devices with cellular reporting. Home sleep testing went from novelty to standard pathway. Consumer wearables made people aware of their sleep patterns for the first time.

So where does the field go next? Here’s an honest assessment — no hype, no crystal ball theatrics.

Diagnostics Are Moving Closer to the Patient

The traditional model — GP referral, specialist consultation, lab sleep study, results review, treatment initiation — works but takes time. In parts of Australia, the wait for a lab polysomnography slot stretches beyond six months.

Consumer and medical-grade wearables are converging. Devices like the Apple Watch already track blood oxygen and sleep stages with reasonable accuracy. They’re not diagnostic instruments yet, but they’re getting closer. The near-term scenario is wearable data serving as a screening layer — flagging individuals who should be referred for formal testing.

Newer form factors — headbands, ear-worn devices, patches — are achieving sleep staging accuracy that would have impressed as a clinical device a decade ago. For patients in regional areas with limited lab access, these technologies represent genuine access improvements.

AI Is Reshaping Interpretation

Sleep study scoring has always been labour-intensive. AI-based automatic scoring has reached accuracy comparable to expert human scorers. A study in the Journal of Clinical Sleep Medicine found a deep learning algorithm agreed with expert consensus as well as individual experts agreed with each other.

The implication isn’t that human scorers become redundant — it’s that workflow changes. AI handles the initial pass; humans review, verify, and manage complex cases.

Beyond scoring, AI models are beginning to predict treatment response. Which patients will tolerate CPAP? Who might do better with an oral appliance? These questions currently rely on clinical intuition and trial-and-error. Predictive models could make first-line treatment selection more accurate.

Personalised Treatment Is Getting Real

Phenotyping — classifying sleep apnea by its underlying cause rather than just severity — is moving toward clinical reality. Research from Danny Eckert at Flinders University has identified distinct traits contributing to OSA: anatomical compromise, low arousal threshold, high loop gain, and poor muscle responsiveness.

A patient with a low arousal threshold might respond to medications that reduce the tendency to wake from mild respiratory events. Another with high loop gain might benefit from oxygen therapy. These approaches are being validated in clinical trials.

Organisations like the team at Team400 are working on data analysis platforms that could help clinicians match patients to optimal treatments based on individual physiological profiles.

Telemedicine Has Changed the Model

CPAP follow-ups are a natural fit for telehealth — clinicians review compliance data remotely and adjust treatment via video call. The Royal Australasian College of Physicians supports ongoing telehealth access for specialist consultations where clinically appropriate.

The broader effect: geography matters less. A patient in rural Queensland can access a Sydney sleep specialist without a day of travel. That’s a genuine improvement in healthcare equity.

Dental Sleep Medicine Is Growing

Mandibular advancement devices are now recognised as first-line for mild-to-moderate OSA. Digital dental impressions and 3D printing are making fabrication faster and more precise. The growth area is combination therapy — oral appliances with positional therapy or lower-pressure CPAP — through clearer pathways established by the Australasian Sleep Association.

What Won’t Change

Sleep medicine will continue to require skilled clinicians who interpret complex presentations. A machine can score a sleep study, but understanding results in the context of a patient’s medications, comorbidities, anatomy, and goals — that’s clinical judgment, and it’s not going anywhere.

Sleep medicine is heading somewhere good. The tools are better, the evidence base is deeper, and access is expanding. The specialty’s best days are ahead.